"BIOPHARMACEUTICAL COMPOSITION ED - Darl Kuhn", IP.COM, IP.COM INC., WEST HENRIETTA, NY, US, 12 July 2019 (2019-07-12), XP013183858, ISSN: 1533-0001 (B1)

ANONYMOUS: "A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)", CLINICALTRIALS.GOV, 4 September 2018 (2018-09-04), pages 1 - 10, XP055911985, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT03656718> [retrieved on 20220412] (B1)

CA-A1- 3 131 052 (B1)

ROSENGREN S. ET AL: "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration", AAPS JOURNAL, vol. 28, no. 5, September 2015 (2015-09-01), pages 1144 - 1156, XP055905865 (B1)

EMA CHMP: "Opdivo", ASSESSMENT REPORT - EMEA/CHMP/76688/2015, 23 April 2015 (2015-04-23), pages 1 - 130, XP055908981 (B1)

JOHNSON MELISSA L. ET AL: "Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors : A Phase 1 Dose-Escalation Trial", JAMA ONCOLOGY, vol. 5, no. 7, July 2019 (2019-07-01), US, pages 999, XP055905849, ISSN: 2374-2437, DOI: 10.1001/jamaoncol.2019.0836 (B1)

DONG WENLIANG: "rHuPH20-facilitated subcutaneous administration of monoclonal antibodies in cancer therapy", IMMUNOTHERAPY, vol. 13, no. 1, 17 November 2020 (2020-11-17), GB, pages 79 - 88, XP055905047, ISSN: 1750-743X, DOI: 10.2217/imt-2020-0204 (B1)